Ellen Linnea Freese Ballegaard, Kristine Lindhard, Morten Lindhardt, Christian Daugaard Peters, Finn Thomsen Nielsen, Ida Nørager Tietze, Rikke Borg, Lene Boesby, Marianne Camilla Bertelsen, Julie Maria Bøggild Brøsen, Donata Cibulskyte-Ninkovic, Jesper Moesgaard Rantanen, Frank Holden Mose, Jan Dominik Kampmann, Alice Skovhede Nielsen, Johanne Kodal Breinholt, Dea Haagensen Kofod, Iain Bressendorff, Peter Vilhelm Clausen, Theis Lange, Lars Køber, Anne-Lise Kamper, Casper Niels Furbo Bang, Christian Torp-Pedersen, Ditte Hansen, Erik L Grove, Gunnar Gislason, Jens Dam Jensen, Jonas Bjerring Olesen, Mads Hornum, Marianne Rix, Morten Schou, Nicholas Carlson
INTRODUCTION: Atrial fibrillation is highly prevalent in patients on chronic dialysis. It is unclear whether anticoagulant therapy for stroke prevention is beneficial in these patients. Vitamin K-antagonists (VKA) remain the predominant anticoagulant choice. Importantly, anticoagulation remains inconsistently used and a possible benefit remains untested in randomised clinical trials comparing oral anticoagulation with no treatment in patients on chronic dialysis. The Danish Warfarin-Dialysis (DANWARD) trial aims to investigate the safety and efficacy of VKAs in patients with atrial fibrillation on chronic dialysis...
February 26, 2024: BMJ Open